Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Subviral Agents

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...

Retrovirus Life Cycles

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...

Myocarditis III: Medical Management

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...

Pneumonia IV: Management

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Effects of early rehabilitation with a physiatrist and a registered therapist operating acute rehabilitation in mechanically ventilated ICU patients: a prospective observational study.

Frontiers in rehabilitation sciences·2026

Same author

Modeling viral shedding and symptom outcomes in oseltamivir-treated experimental influenza infection.

PloS one·2026

Same author

Prediction of cccDNA dynamics in hepatitis B patients by a combination of serum surrogate markers.

PLoS computational biology·2025

Same author

Defects in Nitrogen-Doped ZnO Nanoparticles and Their Effect on Light-Emitting Diodes.

Nanomaterials (Basel, Switzerland)·2024

Same author

Modeling and predicting individual variation in COVID-19 vaccine-elicited antibody response in the general population.

PLOS digital health·2024

Same author

Multiscale modeling of HBV infection integrating intra- and intercellular viral propagation to analyze extracellular viral markers.

PLoS computational biology·2024

Search research articles

Related Experiment Video

Updated: Oct 8, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

[Remdesivir for COVID-19].

Yasuhisa Fujita¹

¹Gilead Sciences, K.K.

Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica

|January 4, 2022

Summary

This summary is machine-generated.

Remdesivir, an antiviral drug, inhibits RNA synthesis and has shown effectiveness against SARS-CoV-2. It received exceptional approval in Japan for treating COVID-19 infections.

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

Related Experiment Videos

Last Updated: Oct 8, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

Area of Science:

Virology
Pharmacology
Infectious Diseases

Background:

Remdesivir is a direct-acting antiviral targeting RNA synthesis.
It demonstrated activity against MERS-CoV and SARS-CoV, prompting development for COVID-19.
COVID-19, a novel coronavirus infection, emerged in December 2019, causing severe respiratory illness.

Purpose of the Study:

To describe the development background of remdesivir for COVID-19 treatment.
To present the clinical results of remdesivir in managing SARS-CoV-2 infections.
To detail the exceptional approval of remdesivir in Japan.

Main Methods:

In vitro and in vivo studies confirmed remdesivir's antiviral activity against SARS-CoV-2.
Clinical studies were initiated in February 2020.
Data from NIAID and Gilead Sciences clinical studies, plus compassionate use, informed the approval.

Main Results:

Remdesivir confirmed in vitro antiviral activity against SARS-CoV-2.
Clinical studies demonstrated therapeutic potential.
Exceptional approval granted in Japan based on study outcomes and compassionate use data.

Conclusions:

Remdesivir is a promising antiviral agent for COVID-19.
Clinical evidence supported its efficacy and safety for SARS-CoV-2 infections.
Exceptional approval in Japan facilitates access to this critical treatment.